21 Nov 2023 Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
21 Nov 2023 Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
21 Nov 2023 Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib
20 Nov 2023 Antibody Target, Technology & Pipeline Database: a cost-effective tool to stay tuned with latest information about therapeutic antibodies
17 Nov 2023 Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
17 Nov 2023 Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
17 Nov 2023 Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
17 Nov 2023 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
16 Nov 2023 Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen
16 Nov 2023 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
16 Nov 2023 Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)
15 Nov 2023 SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases
15 Nov 2023 Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
15 Nov 2023 Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer
15 Nov 2023 Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
15 Nov 2023 Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023
15 Nov 2023 Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
15 Nov 2023 EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
15 Nov 2023 MBrace Therapeutics Raises $85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
15 Nov 2023 TRexBio Announces Development Candidate, TRB-061, a Novel TNFR2 Agonist for the Treatment of Inflammatory Diseases
13 Nov 2023 First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591
13 Nov 2023 Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
10 Nov 2023 Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
09 Nov 2023 Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
09 Nov 2023 Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up